Your search matches the following sites:
PI3K Pathway- clarientinc.com
Activation of the phosphatidylinositol 3-kinase (PI3K)-AKT pathway, regulates many normal cellular processes which include cell proliferation, survival, and motility. For these same reasons, the PI3K pathway also plays an important oncogenic role in many cancer types. PI3K signaling pathways can be deregulated by a variety of mechanisms in human tumors.
Keywords:
EGFR Testing- clarientinc.com
A large body of experimental and clinical work supports the view that EGFR is a relevant target for cancer therapy. The development of selective tyrosine kinase inhibitors has become an important area of drug discovery for the treatment of a variety of solid tumors such as breast, ovarian and colorectal cancers, NSCLC, and carcinoma of the head and neck.
Keywords:
EML4-ALK- clarientinc.com
we have found a novel fusion product between the echinoderm microtubule-associated protein-like4 (EML4) and the anaplastic lymphoma kinase (ALK) in non-small cell lung cancers (NSCLCs). Tumors featuring EML4-ALK fusion constitute one subtype of NSCLC that might be highly sensitive to ALK inhibitors. Herein, we present results of a first large scale study of EML4-ALK fusion in lung cancers.
Keywords:
EGFR- clarientinc.com
The epidermal growth factor receptor (EGFR) is the cell-surface receptor for members of the epidermal growth factor family of extracellular protein ligands. EGFR exists on the cell surface and is activated by binding of its specific ligands, including epidermal growth factor and transforming growth factor α.
Keywords: